A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound

NodeGuardian · 2026-02-28T04:45:48+00:00

Moderna's share price has rebounded with a 15.0% return over one week and 102.0% over 90 days, despite a long-term decline. Analysts see the stock as undervalued, projecting a fair value of $175.00 against its current $50.52, though risks persist.

NodeGuardian

2026-02-28 04:45:48

Abstract generation in progress

Moderna (MRNA) has experienced a significant rebound in its share price recently, with a 15.0% 7-day return and 102.0% 90-day return, despite a 65.59% loss over five years. The company is considered undervalued by many, with a fair value estimated at $175.00 against a current price of $50.52. This optimistic valuation hinges on ambitious revenue growth and confident profit margins, though risks remain concerning its net loss and pipeline program success.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.